Company: SCLXW
Filing Date: 2025-05-14
Form Type: 424B3
Source: 0001193125-25-119846
Chunk: 205

Company: Scilex Holding Co
Filing Date: 2025-05-14
Form: 424B3
Chunk 205
---
 the “December 2024 RDO Warrants”). The combined offering price (a) per share of Common Stock
and accompanying December 2024 RDO Common Warrants was $20.65 and (b) per December 2024 RDO Pre-Funded Warrant and accompanying December 2024

128

RDO Common Warrants was $20.6499. We received approximately $17.0 million in gross proceeds from the December 2024 RDO, before deducting offering fees and expenses. We intend to use the net proceeds from the December 2024 RDO for working capital and general corporate purposes, which may include capital expenditures, commercialization expenditures, research and development expenditures, regulatory affairs expenditures, clinical trial expenditures, acquisitions of new technologies and investments, business combinations and the repayment, refinancing, redemption or repurchase of indebtedness or capital stock. Amendment to Common Stock Purchase Warrant On December 11, 2024, we entered into a warrant amendment (the “Warrant Amendment”) with one of the investors to exercise the outstanding amount of certain warrants that we issued to such investor in the February 2024 BDO on March 5, 2024. Pursuant to the Warrant Amendment, the investor agreed to exercise outstanding warrants to purchase an aggregate of 50,421 shares of Common Stock in cash at an amended exercise price of $20.65 per share. The gross proceeds to us from such exercise was approximately $1.0 million. Future Liquidity Needs We have based our anticipated operating capital requirements on assumptions that may prove to be incorrect and we may use all our available capital resources sooner than we expect. The amount and timing of our future funding requirements will depend on many factors, some of which are outside of our control, including but not limited to:

| • |     | the costs and expenses associated with our ongoing commercialization efforts for ZTlido, GLOPERBA and ELYXYB; |

| • |     | the degree of success we experience in commercializing ZTlido, GLOPERBA and ELYXYB; |

| • |     | the revenue generated by sales of ZTlido, GLOPERBA, ELYXYB and other products that may be approved, if any; |

| • |     | the scope, progress, results and costs of conducting studies and clinical trials for our product candidates, 
 SEMDEXA, SP-103 and SP-104;                                                                                  |

| • |     | the timing